Aurinia terminates EVP R&D Volker Knappertz in restructuring

Aurinia Pharmaceuticals Inc.

Dr. Volker Knappertz, EVP R&D, to be terminated as part of Aurinia's Feb 15 restructuring.
Severance includes 12 months base salary, accrued vacation, performance bonus payout.
Eligible for medical, dental, vision benefits for up to 12 months if release is provided.
Employment agreement terms filed as Exhibit 10.18 to 2023 10-K on Feb 15, 2024.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Volker Knappertz

Executive Vice President, Research and Development

AUPH · Aurinia Pharmaceuticals Inc.

Filed: February 29, 2024, 6:59 PM ET

As part of the restructuring that Aurinia Pharmaceuticals Inc. (Aurinia) announced on February 15, 2024, Aurinia plans to terminate its employment relationship with Dr. Volker Knappertz.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Volker Knappertz was terminated as Executive Vice President, Research and Development at Aurinia Pharmaceuticals Inc..

Action: terminated
Role: Executive Vice President, Research and Development

Exact text from the filing

As part of the restructuring that Aurinia Pharmaceuticals Inc. (Aurinia) announced on February 15, 2024, Aurinia plans to terminate its employment relationship with Dr. Volker Knappertz.

View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-24-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.